AN
Alto Neuroscience, Inc.
ANRO · NYSE
$35.80 +0.70% (+$0.25)
1M +26.58%
Market Cap $1.26B
P/E Ratio -
Div. Yield -
ROE 46.46%
Piotroski F-Score Weak
2/9Valuation
28 /100
Expensive P/B 5.73x
EV/FFO N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
37 /100
Average ROA 33.16%
ROIC 18.43%
Asset turnover 0.00x
Debt
69 /100
Low Int. coverage -36.26x
Debt/Equity 0.03x
Current ratio 14.85x
Stability
44 /100
Moderate Profitable years 0
Beta 1.09x
EPS volatility 49.23%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ANRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amit Etkin
Employees
68
Headquarters
Mountain View
Prihajajoči dogodki
11 NOV.
Earnings
Upcoming earnings report